Orlistat‐induced fulminant hepatic failure

摘要: Orlistat was approved by the Food and Drug Administration in 1998 has been shown to be superior placebo achieving weight loss. It is generally well tolerated. However, severe liver injury reported. We present a case of hepatic failure patient taking orlistat. A 54-year-old African-American woman with hypertension presented failure. She had noticed increasing fatigue, jaundice confusion. used alcohol sparingly denied tobacco or illicit drug use, but over-the-counter orlistat for past two months. Physical examination revealed scleral icterus, jaundice, asterixis slow speech. Laboratory testing showed markedly abnormal function tests coagulopathy. Acute viral autoimmune serologies were negative, as toxicology screen. Liver biopsy necrotic parenchyma likely secondary toxicity. Based upon her clinical presentation time course, pattern seen on lack an alternative plausible explanation, most associated use. continued deteriorate ultimately underwent orthotopic transplantation. Fourteen cases use have reported, four which are detailed literature. This second published usage. Clinicians should aware growing number associating carefully monitor their patients this medication signs dysfunction.